Nicotinamide Mononucleotide (NMN): Difference between revisions

Nicotinamide Mononucleotide (NMN) (view source)

Revision as of 14:31, 5 October 2023

16 bytes added , 5 October 2023

→‎US

VisualWikitext

Strimo

Bureaucrats, Administrators

2,851

edits

@@ Line 12: / Line 12: @@
 While NMN is not approved for human consumption in the EU, consumers may come across NMN products online that appear to be marketed for human use. However, these are officially sold either as chemicals for research and laboratory purposes or as supplements for animals, including dogs and cats. It is important for consumers to recognize the legal status and potential risks of such unapproved substances.
-=== US ===
+=== United States (US) ===
-In November 2022, the [[US Food and Drug Administration (FDA)]] issued a statement saying that NMN may not be sold as a supplement, citing its status as being under investigation as a drug. This development is a reversal of the FDA's previous decision to allow its sale as a new dietary supplement (NDI). The reason for the reversal is unknown, but in December 2021, Metro International Biotech, a startup pharmaceutical company that has developed the NMN formulation MIB-626, wrote to the FDA: "As a company that has instituted publicly available clinical trials on ß-NMN, we request that FDA take the preclusion provision … seriously to protect the rights of companies that have spent significant time and research to develop drug products from competition from dietary supplements". According to Insider, the FDA confirmed that it had considered Metro's request.  <ref>https://www.nmn.com/news/fda-bans-labeling-nmn-as-a-supplement</ref>
+In November 2022, the US [[Food and Drug Administration (FDA)]] issued a statement saying that NMN may not be sold as a supplement, citing its status as being under investigation as a drug. This development is a reversal of the FDA's previous decision to allow its sale as a new dietary supplement (NDI). The reason for the reversal is unknown, but in December 2021, Metro International Biotech, a startup pharmaceutical company that has developed the NMN formulation MIB-626, wrote to the FDA: "As a company that has instituted publicly available clinical trials on ß-NMN, we request that FDA take the preclusion provision … seriously to protect the rights of companies that have spent significant time and research to develop drug products from competition from dietary supplements". According to Insider, the FDA confirmed that it had considered Metro's request.  <ref>https://www.nmn.com/news/fda-bans-labeling-nmn-as-a-supplement</ref>
 ==Different Forms of NMN==